Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
With
Serbian Lymphoma Group
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed cluster of differentiation antigen 20 (CD20) positive Diffuse Large B-Cell Lymphoma according to the World Health Organization/Revised European-American Classification of Lymphoid Neoplasms (WHO/REAL) classification
Age \> or =18 years
Performance status \< or = 2 on the Eastern Cooperative Oncology Group (ECOG) scale
Women of child-bearing potential must agree to use effective contraception for the entire treatment period and during the 12 months thereafter
You may not be if
Transformed lymphoma (secondary to "low-grade" follicular lymphoma)
Grade 1, 2 or 3a follicular lymphoma
Primary or secondary central nervous system (CNS) involvement
Patients with prior or concomitant malignancies except non-melanoma skin cancer or adequately treated in situ cervical cancer
Major surgery (excluding lymph node biopsy) within 28 days prior to registration.
Poor hepatic function: total bilirubin \> 2.0 mg/dl (34 micromol/L), aspartate transaminase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) or alanine transaminase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) or alkaline phosphatase (AP) \> 3 x the upper limit of normal unless these abnormalities are related to lymphoma.
Known human immunodeficiency virus (HIV) infection or active viral hepatitis, specifically hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial
Life expectancy \< 6 months
Known sensitivity or allergy to murine products
Treatment within a clinical trial within 30 days prior to trial entry
Clareo Health | MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma
